Currently, the standard treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is dual antiplatelet therapy (DAPT) with aspirin plus P2Y12 inhibitor [1,2,3]. The gene discussed is P2RY12; the disease is acute coronary syndrome.